Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

electrochemical generator developed in house [6.3]. The reaction was carried out
at ~pH6 for 2 h at 40°C. Yttrium-90 DOTA rituximab was characterized using
HPLC carried out on a TSK G3000SWxL gel column, along with a SWxL guard
column, using 0.05M PO 4 3– buffer, pH6.8, as the mobile phase (see Fig. 6.8). The
radiolabelling yield was ~70%. In the standardized HPLC system, 90 Y DOTA
rituximab had a retention time of 15 min, while free 90 Y 3+ had a retention time of
22 min.
The 90 Y DOTA rituximab reaction mixture was purified by passing through
a PD-10 column and eluted with 0.05M phosphate buffer (pH7.4). The elution
pattern obtained is shown in Fig. 6.9. Figure 6.10 shows the HPLC pattern of
FIG. 6.8. HPLC pattern of 90 Y DOTA rituximab reaction mixture.
FIG. 6.9. Elution profile of 90 Y rituximab DOTA on PD-10 column.
92